Rosuvastatin Tablet, Film Coated
Product Images NDC 70518-4314

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rosuvastatin (NDC 70518-4314). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
This is a description of a medication package for Rosuvastatin 40mg tablets. The package contains 100 tablets and the medication should be protected from moisture. The medication is manufactured by ScieGen in Hauppauge, NY with an NDC number of 70518-4314-00. It should be stored at 20-25°C (58-77°F) with excursions permitted to 15.30°C (59-86°F). The package includes directions for use, and it has been repackaged by RemedyRepack Inc. in Indiana, PA. Keep this and all medication out of the reach of children.*
FDA Label Image

Figure-01 (Figure 1)

Figure-01 (Figure 1)
This text appears to show statistical data comparing the efficacy of RSV versus placebo on a certain outcome. It includes data on the hazard ratio with 95% confidence interval, significance levels, sample sizes, and the number at risk over different time points. The information provided could be part of a clinical trial or study evaluating the effectiveness of RSV compared to a placebo treatment.*
FDA Label Image

Figure-02 (Figure 2)

Figure-02 (Figure 2)
This text appears to be a comparison of outcomes between patients treated with Rosuvastatin 20mg and Placebo 20mg in a study involving 8901 participants. It includes data on the number of events such as cardiovascular death, nonfatal stroke, nonfatal MI, hospitalized unstable angina, and arterial revascularization. The hazard ratios with confidence intervals and p-values are also provided for each event. The study assesses the primary endpoint (MCE) and specifies that cardiovascular death includes fatal MI, fatal stroke, sudden death, and other adjudicated causes of cardiovascular death.*
FDA Label Image

Figure-02 (Figure 3)

Figure-02 (Figure 3)
FDA Label Image

Structural Formula (Rosuvastatin Str)

Structural Formula (Rosuvastatin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.